Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.

Abstract: Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

Abstract: Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.

Abstract: Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

Abstract: Deimmunized botulinum toxin light chain (e.g., botulinum toxin serotype A light chains (BoNT/A-LC)) or fragments thereof are provided. Methods for treating or preventing diseases or disorders comprising administering to a subject a deimmunized botulinum toxin light chain (e.g., BoNT/A-LC) are provided.

Abstract: Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.

Abstract: Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.

Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.

Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.

Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.

Abstract: Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

Abstract: This invention concerns a composition containing a dimerized or trimerized fatty acid amide of a primary alkanolamine that remains clear of suspended solids during storage, making mixtures containing the additive particularly useful to the metalworking industry. The amide may be formed by the condensation of a primary alkanolamine and a dimerized or trimerized fatty acid. When added to an amide of a primary alkanolamine and fatty acid containing a single carboxylic acid group, these molecules are able to prevent crystallization of the amide mixture.

Abstract: This invention concerns a composition containing a dimerized or trimerized fatty acid amide of a primary alkanolamine that remains clear of suspended solids during storage, making mixtures containing the additive particularly useful to the metalworking industry. The amide may be formed by the condensation of a primary alkanolamine and a dimerized or trimerized fatty acid. When added to an amide of a primary alkanolamine and fatty acid containing a single carboxylic acid group, these molecules are able to prevent crystallization of the amide mixture.

Abstract: This invention concerns a composition containing a dimerized or trimerized fatty acid amide of a primary alkanolamine that remains clear of suspended solids during storage, making mixtures containing the additive particularly useful to the metalworking industry. The amide may be formed by the condensation of a primary alkanolamine and a dimerized or trimerized fatty acid. When added to an amide of a primary alkanolamine and fatty acid containing a single carboxylic acid group, these molecules are able to prevent crystallization of the amide mixture.